Document:

Exhibit 10.44

 

Addendum to the

 

Shareholders' Agreement

 

in relation
to the parties' share holdings 

in CureVac N.V. (NL-Amsterdam)

 

dated June 16, 2020

 

between

 

KfW

Palmengartenstr. 5-9

60325 Frankfurt am Main

 

- hereinafter
referred to as "Investor Bund

 

on the one hand

 

and

 

dievini
Hopp BioTech holding GmbH & Co KG

represented by its general partner dievini Verwaltungs GmbH

Johann-Jakob-Astor-Str. 57

69190 Walldorf

 

- hereinafter
referred to as "dievini

 

Mr. Dietmar Hopp

Johann-Jakob-Astor-Str. 57

69190 Walldorf

 

- hereinafter
referred to as "DH" - -

 

and

 

DH-LT Investments
GmbH

Opelstraße 28

68789 St. Leon-Rot

 

on the other hand

 

- Investor
Bund, dievini, DH and DH-LT Investments GmbH

 

hereinafter
jointly referred to as the "Parties" or individually as a "Party

 

    	 	 	Page 1of 6

     

    

 

Addendum to the Addendum to the

Shareholders' Agreement between Investor
Bund, dievini and DH

 

Preamble

 

	A	In clause 8 ("Investment Commitment DH")
of the shareholders' agreement concluded between the parties
(with the exception of DH-LT Investments GmbH) with regard to the parties'
shareholdings in CureVac N.V. (NL-Amsterdam) dated 16 June 2020 ("Shareholders'
Agreement"), DH has undertaken to invest an amount of EUR 100 million
into CureVac N.V. on the occasion of the IPO
in order to acquire shares at economic terms and in particular at a share price corresponding to the issue price of a share
in the IPO ("concurrent private placement") ("Investment Amount").

 

	B	DH intends to fulfil this obligation not personally, but rather through DH-LT Investments GmbH,
headquartered in St. Leon-Rot, registered in the Commercial Register of the Local Court in Mannheim under HRB 732866 ("DH-LT"),
of which DH is the sole shareholder.

 

	C	Therefore, the other parties and DH-LT agree to include
DH-LT in the Shareholder Agreement alongside DH by way of this Addendum to the Shareholders'
Agreement.

 

This aforesaid, the Parties
agree on the following:

 

	1	Accession of DH-LT to the Shareholders’
Agreement; Consent of the other Parties

 

DH-LT
hereby accedes to the shareholders' agreement alongside of DH. DH-LT shall therefore
have the same rights and obligations as DH under the shareholders' agreement. The
shares in CureVac N.V. already acquired or to be acquired in the future by DH-LT in the course of the concurrent private
placement shall be deemed IPO shares within the meaning of the Shareholders'
Agreement.

 

	1.2	In particular, but without limitation, DH-LT shall be obligated under
clause 8, 2nd sentence in connection with clause 4.5 of the shareholders'
agreement to exercise the rights from IPO shares in the case of resolutions
of the general meeting on Restricted Items of Resolution in the same way as the voting
rights from the Restricted Shares.

 

    	 	 	Page 2of 6

     

    

 

Addendum to the Addendum to the

Shareholders' Agreement between Investor
Bund, dievini and DH

 

	1.3	For the avoidance of doubt, even with DH-LT's accession to the shareholders'
agreement, as described above, the investment amount is only due and payable
once.

 

	1.4	The other Parties hereby
agree to DH-LT's accession to the Shareholders' Agreement as described in
clause 1.1.

 

	2	Notices to DH-LT

 

All declarations
and other notices from and in connection with the Shareholders’ Agreement and
this addendum to the Shareholders’ Agreement shall be sent by the parties
to the persons listed below at the contact details, who shall act as authorized service agents for DH-LT until such authorization
is revoked:

 

DH-LT Investments GmbH:

 

Opelstrasse 28

68789 St. Leon-Rot

 

Fax:
+ 49 (0) 6227 8608 470

E-Mail: contact@dievini.com

 

each with a copy:

 

Prof. Dr. Christof Hettich

c/o RITTERSHAUS Rechtsanwälte Partnerschaftsgesellschaft mbB

Harrlachweg 4

68163 Mannheim

 

Fax:
+49 (0) 621 4256 250

E-Mail: christof.hettich@rittershaus.net

 

	3	Final provisions

 

	3.1	The provisions of the shareholders' agreement shall
otherwise remain unchanged and continue to apply.

 

    	 	 	Page 3of 6

     

    

 

Addendum to the Addendum to the

Shareholders' Agreement between Investor
Bund, dievini and DH

 

	3.2	Terms defined in this Addendum (including the list of parties and the preamble) shall have the
same meaning when they are written in small caps. Terms written in small
caps in this Addendum and not defined separately in this Addendum shall have the meaning assigned to them in the Shareholders’
Agreement.

 

	3.3	This Addendum is subject to the laws of the Federal Republic of Germany.

 

	3.4	Revisions or amendments to this Addendum or an agreement on its cancellation must be made in writing
to be effective. The written form shall not be fulfilled in this respect by means of telecommunication transmission (fax), exchange
of letters, electronic form (e-mail) or other text form (sec 126b German Civil Code (BGB)). The requirement of written form requirement
agreed herein may only be waived, if the requirement of written form is complied with. Oral agreements do not exist.

 

	3.5	Should individual provisions of this amended are or become invalid or unenforceable or should this
Addendum contain gaps, the validity of the remaining provisions of this Addendum shall unaffected. In place of the invalid, unenforceable
or missing provision, such valid provision shall be deemed to be agreed which the parties
would reasonably have agreed upon if they had been aware of the invalidity, unenforceability or gap at the time of conclusion
of this Addendum. If any provision of this Addendum is or becomes invalid because of the scope of performance or time periods agreed
therein, the scope of performance or time periods agreed in the provision shall be adjusted to the legally permissible scope(s) or
periods which comes closest to the agreed scope(s) or measure. The parties agree
that the above provisions not only represent a reversal of the burden of proof, but that § 139 BGB is waived in its
entirety.

 

- intentionally left blank -

 

    	 	 	Page 4of 6

     

    

 

Addendum to the Addendum to the

Shareholders' Agreement between Investor
Bund, dievini and DH

 

Walldorf, 14.08.2020

 

 

	/s/ Dietmar Hopp	 
	Dietmar Hopp	 

 

 

 

Frankfurt,

 

KfW

 

 

 

	/s/ Dr. Nils Reichhelm	 	/s/ Dr. Elina Pradkhan
	Dr. Nils Reichhelm	 	Dr. Elina Pradkhan

 

 

 

Walldorf, ............................

 

dievini
Hopp BioTech holding GmbH& Co KG represented by

 

dievini Verwaltungs GmbH, which in turn
is represented by

 

 

 

	 	 	 
	/s/ Dietmar Hopp	 	/s/ Dr. Mathias Hothum
	Dietmar Hopp	 	Dr. Mathias Hothum

 

    	 	 	Page 5of 6

     

    

 

Addendum to the Addendum to the

Shareholders' Agreement between Investor
Bund, dievini and DH

 

 

St. Leon-Rot, 14.08.2020

 

DH-LT Investments GmbH

 

 

	 	 
	/s/ Dietmar Hopp	 
	Dietmar Hopp	 

 

    	 	 	Page 6of 6Exhibit 10.46

 

REDACTED

Certain identified
information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely
cause competitive harm if publicly disclosed.

 

SECOND AMENDMENT TO

 

COLLABORATION

 

AND LICENSE

 

AGREEMENT

 

Dated 19 December 2019

 

 

 

BETWEEN

 

 

 

GENMAB B.V.

 

 

AND

 

 

CUREVAC AG

 

     

     

    

 

SECOND AMENDMENT TO COLLABORATION AND LICENSE
AGREEMENT

 

This SECOND AMENDMENT TO COLLABORATION
AND LICENSE AGREEMENT (“ Second Amendment”) is made the 15thnd day of December 2020 (“Second Amendment
Effective Date”), by and between:

 

Genmab
B.V., KvK no. 3016 9902, a Dutch corporation having its principal office at Uppsalalaan 15, 3584 CM Utrecht, the Netherlands
(“Genmab”); and

 

CureVac
AG, a German corporation having its principal office at Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany
(“CureVac”).

 

(Genmab and CureVac are sometimes
hereinafter referred to collectively as the "Parties" or individually as a "Party")

 

RECITALS:

 

	A.	Genmab and CureVac entered into a Collaboration and License Agreement dated 19 December 2019 (the
 “Agreement”); and

 

	B.	Under
the Agreement the Parties committed to negotiate and enter into a clinical supply agreement within [*****] after the Effective
Date of the Agreement.

 

	C.	Genmab and CureVac then
entered into a First Amendment to Collaboration and License Agreement dated 19 December 2019 (the “First Amendment”)
to extend the deadline to negotiate and enter into a clinical supply agreement within [*****] after the Effective Date of the
Agreement

 

	D.	Genmab and CureVac would like to again extend the term for entering into such clinical supply agreement.

 

NOW, THEREFORE, in consideration
of the premises and the mutual covenants and agreements herein contained, and for good and valuable consideration the receipt and
sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree to the following:

 

	1.	Except as otherwise defined herein, the words and phrases in the Agreement shall have the same
meaning in this Second Amendment.

 

	2.	The first sentence of Section 6.2 of the Agreement is hereby deleted in its entirety and replaced
with the following:

 

“6.2. No
later than [*****], the Parties will enter into a clinical supply agreement and related agreements (including a quality
agreement) according to which CureVac shall Manufacture or have Manufactured for Genmab by an approved subcontractor under
Section 5.11 or by a CMO approved by Genmab, and will supply or have supplied to Genmab, Genmab’s demand for the Single
Antibody Product which is the subject of the First Program Research Plan (whether related to the First Collaboration Target
or any Replacement Target) to perform Clinical Phase I Studies (“Early Clinical Supply Agreement”).
[...]”

 

For avoidance of doubt, the
remainder of Section 6.2 of the Agreement shall remain in effect unchanged.

 

    1

     

    

 

	3.	This Second Amendment shall be subject to the same governing law as set forth in Section 17.4 of
the Agreement.

 

	4.	Save as set forth in this Second Amendment, all other terms and conditions of the Agreement shall
remain in full force and effect.

 

	5.	The Parties agree that this Second Amendment may be signed using a DocuSign® electronic signature.
Such electronic signature is the legally binding equivalent to a Party’s handwritten signature and it has the same validity,
enforceability and meaning as a handwritten signature and the Parties hereby waive any objection to the contrary.

 

***

 

IN WITNESS WHEREOF, the Parties
hereto have caused this Second Amendment to be executed and delivered as of the Second Amendment Effective Date.

 

	Genmab B.V.	 	CureVac AG
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	By:	/s/ Birgitte Stephensen	 	By:	/s/ Daniel Babka
	 	 	 	 	 
	 	 	 	 	 
	Name:	Birgitte Stephensen	 	Name:	Daniel Babka
	 	 	 	 	 
	 	 	 	 	 
	Title:	Senior Vice President, IPR & Legal	 	Title:	Senior Legal Counsel
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	By:	/s/ Dr. Ulrich Kruse
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	Name:	Dr. Ulrich Kruse
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	Title:	Senior Director IP Licensing

 

    2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]